NM_001165963.4(SCN1A):c.2302C>G (p.Pro768Ala)

Zorevunersen, a TANGO (Targeted Augmentation of Nuclear Gene Output) antisense oligonucleotide, has shown clinical benefit in a pivotal NEJM-published trial for Dravet syndrome by upregulating productive SCN1A mRNA from the wild-type allele. This approach addresses SCN1A haploinsufficiency by blocking a naturally occurring nonproductive poison exon inclusion event, thereby increasing functional Nav1.1 protein levels. For missense variants like p.Pro768Ala that produce a partially functional channel protein, the therapeutic benefit may depend on whether increasing wild-type allele output can adequately compensate.

A 2026 NEJM publication (PMID: 41780062) reported results from a clinical trial of zorevunersen in children and adolescents with Dravet syndrome, demonstrating clinically meaningful reduction in convulsive seizure frequency. The ASO mechanism was further elucidated by Han et al. (JCI Insight 2025; PMID: 39946203), who showed that antisense oligonucleotides can modulate aberrant inclusion of poison exons in SCN1A transcripts, effectively increasing the pool of productive mRNA from the functional allele. A comprehensive review in CNS Drugs (2026; PMID: 41712149) contextualizes zorevunersen among emerging RNA-based and gene therapies for Dravet syndrome. The p.Pro768Ala variant (ClinVar variation ID 3017016) is classified as likely pathogenic and is located in the S1-S2 linker region of domain II of Nav1.1. Proline at position 768 is highly conserved across voltage-gated sodium channels, and substitution to alanine is predicted to alter channel gating properties. In cases where the missense allele produces a partially functional channel, the TANGO strategy of boosting wild-type allele expression could still provide net therapeutic benefit by increasing the total pool of functional Nav1.1.

The TANGO approach specifically targets haploinsufficiency mechanisms. For gain-of-function missense variants, increasing wild-type allele expression may be beneficial but does not silence the mutant allele. Variant-specific efficacy data for p.Pro768Ala have not been reported in clinical trials. Intrathecal delivery requires repeated lumbar punctures in pediatric patients, raising compliance and procedural risk concerns. Long-term effects of sustained SCN1A upregulation on neuronal excitability remain under investigation. The approach does not address the developmental damage that may have already occurred before treatment initiation, particularly in patients diagnosed after infancy.